Skip to main content

Table 4 Win ratio analysis in subgroups defined by sex and baseline FVC

From: Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease

Subgroup

N

Win ratio (95% CI)

p-value

AVA

ALG

Sex

    

 Male

27

25

2.03 (0.92–4.48)

0.078

 Female

24

24

2.93 (1.19–7.22)

0.020

Baseline FVC % predicted

    

  ≥ 55%

35

30

3.75 (1.65–8.53)

0.002

  < 55%

16

19

1.21 (0.48–3.05)

0.685

  1. ALG alglucosidase alfa, AVA avalglucosidase alfa, CI confidence interval, FVC forced vital capacity
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172